• SERCA-ER Stress and HSC Mobilization: Study Insights

  2026-09-30

  Li, Xu, and Huang identify SERCA-dependent endoplasmic reticulum stress as a regulator of hematopoietic stem cell mobilization. Using BHQ, in vivo mouse assays, functional colony formation, cell-based knockdown, and molecular analyses, the study connects SERCA inhibition to the CaMKII–STAT3–CXCR4 axis and reduced HSC retention in bone marrow.

• Streptavidin Magnetic Beads: K1301 Workflow Guide

  2026-09-30

  K1301 enables magnetic capture of biotinylated proteins, peptides, antibodies, sugars, oligonucleotides, and nucleic acids from complex samples. It is appropriate when the target is biotinylated or can be biotinylated, but it is not a direct capture reagent for unbiotinylated molecules and requires validation for sensitive downstream assays.

• Irinotecan (CPT-11): From Mechanism to Translation

  2026-09-29

  A translational perspective on Irinotecan as a prodrug-driven topoisomerase I inhibitor, with practical guidance for connecting activation biology, DNA damage and apoptosis induction, colorectal cancer models, xenograft studies, and clinically informed experimental strategy.

• Quercetin Workflow for PI3K and Ferroptosis Research

  2026-09-29

  Build a reproducible Quercetin workflow that separates PI3K signaling, mitochondrial apoptosis, and ferroptosis rather than treating them as interchangeable endpoints. The approach combines practical dosing, lipid-peroxidation assays, ACSL4-pathway validation, and troubleshooting for cancer research and liver-injury models.

• Leonurine Reframes Doxorubicin Cardiotoxicity

  2026-09-28

  The reference study identifies cardiac vascular endothelial cells as early sensors and amplifiers of doxorubicin injury, linking endothelial cGAS–STING activation to NLRP3-mediated pyroptosis, pathogenic extracellular vesicles, and cardiomyocyte mitochondrial dysfunction. It also presents leonurine as a direct STING inhibitor that binds Tyr261, suggesting an upstream endothelial strategy for interrupting the self-reinforcing injury loop.

• Streptavidin Magnetic Beads for Mechanistic Assays

  2026-09-28

  Explore how streptavidin magnetic beads can support the stepwise investigation of RNA–protein interactions and signaling hypotheses, using SNORA38B-driven lung cancer biology as a case study. This article connects mechanistic evidence to practical capture design while distinguishing published findings from workflow recommendations.

• Reactive Oxygen Species Assay Kit for TrxR Studies

  2026-09-27

  Connect thioredoxin reductase and MAPK research with a live-cell readout of intracellular superoxide using a practical DHE workflow. Learn how to set up controls, interpret fluorescence cautiously, and troubleshoot oxidative-stress measurements without treating them as proof of pathway activity.

• BCECF for Extracellular pH Assays

  2026-09-26

  Use BCECF to quantify extracellular pH shifts alongside macrophage efferocytosis, ion-transport, or metabolism experiments—without mistaking a medium change for an intracellular signal. This practical workflow covers ratiometric measurement, calibration, controls, and limits when adapting the assay to neuropathic-pain research.

• LY2603618: Checkpoint Inhibition Meets Genome Surveillance

  2026-09-25

  LY2603618 is a Chk1 inhibitor for studying how checkpoint disruption changes DNA damage and cell-cycle outcomes. This article connects those assays to nuclear cGAS genome surveillance while clarifying why findings about CHK2 cannot be assumed to describe Chk1.

• 2D and 3D Models for Radiosensitizer Screening

  2026-09-24

  A 2025 lung cancer study compared inhibitors of DNA repair and apoptosis pathways in matched 2D and 3D assays. The models produced broadly similar radiosensitization patterns, while extracellular-matrix cultures also revealed context-dependent responses that can inform preclinical prioritization.

• Praeruptorin A: Workflows for Ferroptosis Research

  2026-09-24

  Use Praeruptorin A to connect intracellular Fe²⁺ screening with DMT1, ferroptosis, and cardiac-injury readouts in doxorubicin models. This workflow also shows how to explore inflammatory-barrier and tumor-invasion questions without treating evidence from different disease models as interchangeable.

• Annexin-V Maps Cardiomyocyte Death After Cardiac I/R

  2026-09-23

  This mouse study used labeled recombinant human annexin-V to detect phosphatidylserine exposure in the heart after ischemia and reperfusion, providing an in situ readout earlier than DNA-fragmentation assays alone. The increase in annexin-V-positive cardiomyocytes with longer ischemia or reperfusion, and its reduction after cell-death-pathway intervention, illustrates how the method can help characterize injury timing and evaluate therapeutic strategies.

• Streptavidin-FITC for PFOS Sertoli Assays

  2026-09-23

  Streptavidin-FITC converts biotinylated antibodies, probes, and proteins into a flexible fluorescence workflow for studying PFOS-associated Sertoli-cell injury. This guide connects the ATF2/WT1 mitochondrial findings to practical immunofluorescence, tissue staining, and flow cytometry designs, with controls and troubleshooting for reproducible signal.

• LNP Charge and V-ATPase Govern Nucleic Acid Delivery

  2026-09-22

  The 2026 International Journal of Pharmaceutics: X study proposes that lipid nanoparticle surface charge and target-cell V-ATPase activity jointly determine functional nucleic acid delivery. Its in vitro, in vivo, perturbation, and protein-corona experiments suggest that delivery tropism reflects compatibility between nanoparticle properties and intracellular processing capacity, rather than particle design alone.

• GSK3 Inhibition in Mycobacterium tuberculosis Infection

  2026-09-22

  A 2024 iScience study identified glycogen synthase kinase 3 as a host pathway that supports intracellular Mycobacterium tuberculosis growth. By combining pharmacological screening, CRISPR knockout, RNA interference, and phospho-proteomics, the authors provide a mechanistic foundation for host-directed tuberculosis therapy rather than another pathogen-directed antibiotic strategy.

8118 records 1/542 page Next 12345 下5页 Last page